Immatics at PEGS Europe 2026

Nov 16–19, 2026 Lisbon, Portugal ~1.5k attendees Website

Immatics brings 3 presentations to PEGS Europe 2026 in Lisbon. Its program centres on T cell receptor approaches to cancer, covering both TCR T cell therapy and bispecifics, plus where clinical immunotherapy outcomes stand. It presents a single-chain TCR bispecific built to hit several targets at once and clinical progress against PRAME-positive cancers.

Organization	PEGS Europe 2026 Attendance
Immatics Tübingen, Germany
immatics.com Biotech Develops TCR-based cell therapies and TCR bispecifics against cancer targets.	Talk Tue Nov 17 8:30am–9:00am Unlocking Target Multiplexing in Solid Cancers with a Novel Single-Chain TCR Bispecific Approach Safety and Efficacy of Bispecific and Multispecific Antibodies Talk Thu Nov 19 8:30am–9:00am Targeting PRAME+ Cancers: Clinical Progress across TCR T Cell Therapy and Bispecific Approaches Next-Generation Immunotherapies Panel Thu Nov 19 3:35pm–4:15pm Clinical Outcomes in Immunotherapy—Where Are We Now? Next-Generation Immunotherapies · with Accession Therapeutics, BioInvent, Dr. Rosell Oncology Institute, Dexeus University Hospital +2 more

Organization

PEGS Europe 2026 Attendance

Immatics

Tübingen, Germany

immatics.com

Biotech

Develops TCR-based cell therapies and TCR bispecifics against cancer targets.

Talk

Tue Nov 17
8:30am–9:00am

Unlocking Target Multiplexing in Solid Cancers with a Novel Single-Chain TCR Bispecific Approach

Safety and Efficacy of Bispecific and Multispecific Antibodies

Talk